AbbVie Inc.
www.abbvie.com
Latest From AbbVie Inc.
Novartis Targets Ten Indications For Cosentyx
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Big Pharma’s Aging Antibodies Cling To Their Crowns
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Finance Watch: Big Money For Big Goals Met By Reata, CRISPR, Karuna
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
US Senate Finance Drug Pricing Bill Would Have ‘Negligible’ Impact, Analyst Predicts
Now that US drug pricing reform seems inevitable, the Senate bill offers the most positive outcome for industry, Bernstein analyst Ronny Gal suggests.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Neurology, Nervous System
- Renal System
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Company Type
- Big Pharma
- Parent & Subsidiaries
- AbbVie Inc.
- Senior Management
-
Richard A Gonzalez, Chmn. & CEO
Robert A Michael, EVP, CFO
Michael E Servino, MD, Pres.
Carlos Alban, Chief Commercial Officer - Contact Info
-
AbbVie Inc.
Phone: (847) 937-6100
1 N. Waukegan Rd.
North Chicago, IL 60064
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice